2024-03-28T21:06:25Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_17C4CCBCEC16
2024-03-23T01:54:44Z
serval:BIB_17C4CCBCEC16
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
10.1016/j.cmi.2018.02.002
000454246100004
29447987
Winthrop
K.L.
author
Mariette
X.
author
Silva
J.T.
author
Benamu
E.
author
Calabrese
L.H.
author
Dumusc
A.
author
Smolen
J.S.
author
Aguado
J.M.
author
Fernández-Ruiz
M.
author
article
review
2018-06
Clinical microbiology and infection
1469-0691
1198-743X
journal
24 Suppl 2
S21-S40
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal/adverse effects
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/administration & dosage
Antibodies, Monoclonal, Humanized/adverse effects
Antibodies, Monoclonal, Humanized/therapeutic use
Biological Therapy/adverse effects
Clinical Trials as Topic
Communicable Disease Control
Communicable Diseases/immunology
Communicable Diseases/therapy
Complement System Proteins/drug effects
Dermatologic Agents/administration & dosage
Dermatologic Agents/adverse effects
Humans
Immunocompromised Host
Immunoglobulins/drug effects
Interleukin-17/antagonists & inhibitors
Interleukins/antagonists & inhibitors
Interleukins/immunology
Meningococcal Vaccines/administration & dosage
Molecular Targeted Therapy/adverse effects
Anakinra
Brodalumab
Canakinumab
Eculizumab
Infection
Ixekizumab
Prevention
Rilonacept
Secukinumab
Tocilizumab
eng
60_published
peer-reviewed
Publication types: Consensus Development Conference ; Journal Article ; Review
Publication Status: ppublish